Bioqual Stock

Bioqual EBIT

The EBIT of Bioqual (BIOQ) as of Jul 14, 2026 is -1.90 M USD. In the previous year, EBIT was -19,600.00 USD — a change of 9,573.47% (lower).

EBIT

-1.90 MUSD

YoY

9,573.47%

Last updated:

In 2026, Bioqual's EBIT was -1.90 M USD, a 9,573.47% increase from the -19,600.00 USD EBIT recorded in the previous year.

The Bioqual EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (M USD)
Date
EBIT (M USD)
Jan 1, 2018
5.27 base
Jan 1, 2019
3.58 base
Jan 1, 2020
5.32 base
Jan 1, 2021
8.56 base
Jan 1, 2022
6.53 base
Jan 1, 2023
1.10 base
Jan 1, 2024
-0.02 base
Jan 1, 2025
-1.90 base
YEAREBIT (M USD)
2025 -1.90
2024 -0.02
2023 1.10
2022 6.53
2021 8.56
2020 5.32
2019 3.58
2018 5.27
2017 6.54
2016 4.72
2015 3.24
2001 0.57
2000 0.24
1999 0.53
1998 0.08
1997 0.08
1996 0.16
1995 0.37
1994 0.47
1993 0.42
Access this data via the Eulerpool API

Bioqual Revenue

Bioqual Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
35.89 M USD
5.27 M USD
3.66 M USD
Jan 1, 2019
39.48 M USD
3.58 M USD
2.83 M USD
Jan 1, 2020
46.36 M USD
5.32 M USD
4.23 M USD
Jan 1, 2021
57.68 M USD
8.56 M USD
6.33 M USD
Jan 1, 2022
66.15 M USD
6.53 M USD
5.26 M USD
Jan 1, 2023
62.66 M USD
1.10 M USD
835,600.00 USD
Jan 1, 2024
58.59 M USD
-19,600.00 USD
483,500.00 USD
Jan 1, 2025
48.87 M USD
-1.90 M USD
-1.05 M USD

Bioqual Margins

Bioqual stock margins

The Bioqual margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bioqual. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bioqual.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
24.31 %
14.69 %
10.21 %
Jan 1, 2019
18.77 %
9.08 %
7.17 %
Jan 1, 2020
20.90 %
11.48 %
9.13 %
Jan 1, 2021
24.23 %
14.83 %
10.97 %
Jan 1, 2022
19.66 %
9.88 %
7.95 %
Jan 1, 2023
13.80 %
1.76 %
1.33 %
Jan 1, 2024
12.68 %
-0.03 %
0.83 %
Jan 1, 2025
9.05 %
-3.88 %
-2.14 %

Bioqual Stock analysis

What does Bioqual do? Bioqual Inc. is an emerging biotechnology company based in Maryland, USA. The company was founded in 1988 with the aim of developing innovative solutions and services for the life sciences and pharmaceutical industry. The founding of Bioqual is closely connected to the emergence of new technologies in the field of biotechnology and genomics research. The company has always been committed to developing innovative products and services that contribute to improving the diagnosis and treatment of diseases, accelerating or facilitating the development of new drugs, and enhancing the quality of animal testing. In its early years, Bioqual primarily focused on the development of diagnostic test systems for animal diseases. In the 1990s, the company expanded its scope to research on infectious diseases and vaccine development. Since 2000, Bioqual has shifted its focus to drug discovery and preclinical studies. Today, Bioqual offers a wide range of products and services in various areas. These include immunological assays, cell culture and microbiology laboratory services, preclinical studies and animal testing services, as well as support in the development of new drugs. An important business model of Bioqual is collaboration with other companies. The company is a key partner for biotech and pharmaceutical companies involved in the development of new drugs and therapies. Bioqual offers preclinical studies and animal testing services to test the effectiveness and safety of new drugs. Partner companies can thus pool their resources and accelerate the testing phase. Bioqual also has its own research and development department and collaborates with academic and medical institutions in the development of new diagnostic and therapeutic methods. Another important area for Bioqual is animal testing services. The company offers specialized animal testing services, including the creation of animal models, conducting studies on the efficacy, pharmacokinetics, and toxicity of substances, as well as regulatory consulting services. In recent years, Bioqual has expanded its presence in the field of diagnostics and treatment of infectious diseases. The company offers serological assays and PCR tests to diagnose infections caused by viruses, bacteria, and parasites. Additionally, Bioqual is involved in the development of vaccines against a variety of infectious diseases, including HIV, Hepatitis C, Zika, and West Nile Virus. The products and services of Bioqual are applied in various areas of life sciences and medicine. They are utilized by pharmaceutical and biotech companies, government agencies, academic institutions, and medical laboratories. Bioqual has shown strong growth in recent years. The company continuously invests in research and development of new products and services to meet the needs of its customers. The company also has a strong presence in various global markets, particularly in Europe, Asia, and South America. Bioqual has established a reputation as an innovative and reliable company in the biotechnology and pharmaceutical industry. With its wide range of products and services and close collaboration with other companies, Bioqual positions itself as a key partner in the development of new diagnostic and therapeutic methods, as well as the exploration of infectious diseases and new drugs. Bioqual is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Bioqual's EBIT

Bioqual's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Bioqual's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Bioqual's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Bioqual’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Bioqual stock

EBIT of Bioqual is -1.90 M USD in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Bioqual

All Key Metrics — Bioqual